Strong volume growth in Pharmaceuticals and
Sandoz: Group sales up 19% in USD (+11% in local currencies); Novartis is one of the fastest growing
top-ten pharmaceutical companies

Pharmaceuticals steadily gaining market share
in all major markets, with sales growth of 18%
in USD, driven by the Cardiovascular and Oncology
franchises

Consumer Health ongoing sales up 24% driven by
60% sales growth at Sandoz

With seven major approvals and 79 projects in
clinical development and registration Novartis has
one of the leading pipelines in the industry

Double-digit (16%) rise in full-year operating income
is driven by volume expansion, product mix enhance-
ments and productivity gains

Net income is up 6% to a new record level of
USD 5.0 billion, lifting earnings per share by 8%

Based on solid performance, a dividend increase
of 5% to CHF 1.00 per share will be proposed to
shareholders